Here's Why Galapagos Stock Is Falling Today
Shares of Galapagos (NASDAQ: GLPG), a biopharmaceutical company, are under pressure following clinical trial readouts for a couple of new drug candidates in phase 1 studies. Disappointing results from the company's Toledo program pushed the stock 13.1% lower as of 3:52 p.m. EDT on Thursday.
Following the implosion of Jyseleca in the U.S., Galapagos has leaned on its early clinical-stage pipeline to get attention from investors. The company has invested heavily in the Toledo program, which is a series of new drug candidates that target salt inducible kinases.
Image source: Getty Images.
Source Fool.com